Gauge, pain and flow rate
Skin thickness at the standard injection sites is approximately two millimetres in adults and varies remarkably little with body mass. That single finding is why short…
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 3 of 5 of this archive, newest first.
Skin thickness at the standard injection sites is approximately two millimetres in adults and varies remarkably little with body mass. That single finding is why short…
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The document is four pages. Three of them are about dates.
The observation that closes a facility is rarely the dramatic one.
Reported from the analysis, not from a warning notice.
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
The evidence base is thin and the document says so, which is to its credit.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
Two signatures — one who performed the work, one who approved its release — are the ordinary regulated convention and are almost unknown here.
The trials measured mass. Nobody measured whether the participants got weaker.
Reported from the sessions, and from the two hours afterwards.
The route did not close because of a rule about peptides.
Efficacy was never the question in this appraisal. Duration of treatment was.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
The observation that closes a facility is rarely the dramatic one.
The evidence base is thin and the document says so, which is to its credit.
Follow the resin, not the catalogue.
The supplier has not disputed the finding. It has not explained the gap either.
What adding GIP activity does, on the current evidence, and what remains unresolved.
A stability programme needs a protocol, defined conditions, a stability-indicating method and time. Time is the ingredient no commercial testing service can sell.
The document is four pages. Three of them are about dates.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The report states the gradient, the wavelength and the integration threshold, which is more than most.
A survey of what the meta-analyses support, with the populations named.
A twelve-analyte panel in a perfectly healthy person has roughly even odds of producing at least one flagged result.
Almost every case involves a change — a new vial, a new syringe size, a new supplier — carried forward with an old number.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The evidence base is thin and the document says so, which is to its credit.
A proper account of an operation that existed, and of what closing it cost.
The observation that closes a facility is rarely the dramatic one.
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The route did not close because of a rule about peptides.
A proper account of an operation that existed, and of what closing it cost.
Efficacy was never the question in this appraisal. Duration of treatment was.
What a verification mark would have to carry to be checkable: a date, a lot, a method, a submitter and a link to the report.
The graduation interval differs between barrel sizes, and a 1 mL barrel is frequently marked in two-unit steps. Reading one as though it were marked in single units halves…